Paper Infomation
The Short-Term Efficacy and Safety of Anlotinib Combined With Chemotherapy in Treatment of Advanced Soft Tissue Sarcoma
Full Text(PDF, 28KB)
Author: Yaping Wang
Abstract: Soft tissue sarcoma has a strong tendency of local recurrence and metastasis, and the treatment results after metastasis are not ideal. Alonitide, as a newly developed oral small molecule RTK inhibitor, has good results on STS. This article aims to summarize the results of anlotinib combined with chemotherapy in the treatment of advanced soft tissue sarcoma, and to provide indications for subsequent treatment.
Keywords: Anlotinib, Advanced Soft Tissue Sarcoma, Chemotherapy
References:
[1] Fletcher CD, Hogendoorn PC, Mertens F, Bridge J. WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. Lyon: IARC press; 2013.
[2] Judson I, Verweij J, Gelderblom H, Hartmann JT, Schoffski P, Blay JY, Kerst JM, Sufliarsky J, Whelan J, Hohenberger P, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014; 15:415–23.
[3] Ryan CW, Merimsky O, Agulnik M, Blay JY, Schuetze SM, Van Tine BA, JonesRL, Elia s AD, Choy E, Alcindor T, et al. PICASSO III: A phase III, placebocontrolled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma. J Clin Oncol. 2016; 34:3898-3905.
[4] Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, Agulnik M, Cooney MM, Livingston MB, Pennock G, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016; 388:488–97.
[5] Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y, et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci. 2018; 109:1207–19.
[6] Taurin S, Yang CH, Reyes M, Cho S, Jarboe EA, Werner TL, et al. Abstract 3244: treatment of endometrial cancer cells with a new small tyrosine kinase inhibitor targeting mutated fibroblast growth factor receptor-2. Cancer Res. 2017; 77(13 Supplement):3244.
[7] Lin B, Song X, Yang D, Bai D, Yao Y, Lu N, et al. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1. Gene. 2018; 654:77–86.
[8] Taurin S, Yang CH, Reyes M, Cho S, Coombs DM, Jarboe EA, et al. Endometrial cancers harboring mutated fibroblast growth factor receptor 2 protein are successfully treated with a new small tyrosine kinase inhibitor in an orthotopic mouse model. Int J Gynecol Cancer. 2018; 28:152–60.
[9] van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012; 379:1879–86.
[10] Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 2009; 27:3126–32.
[11] Cassier PA, Gelderblom H, Stacchiotti S, Thomas D, Maki RG, Kroep JR, et al. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer. 2012; 118:1649–55.
[12] Stacchiotti S, Negri T, Libertini M, Conca E, Castelli C, Tazzari M, et al. Sunitinib malate in solitary fibrous tumor (SFT). Ann Oncol. 2012; 23:3171–9.
[13] Valentin T, Fournier C, Penel N, Bompas E, Chaigneau L, et al. Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO). Investig New Drugs. 2013; 31:1626–7.
[14] Butrynski JE, D'Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, et al. Crizotinib in ALKrearranged inflammatory myofibroblastic tumor. N Engl J Med. 2010; 363:1727–33.
[15] Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014; 370:1189–97.
[16] CHI Y , FANG Z , HONG X , et al .Safety and efficacy of anlotinib , a multikinase angiogenesis inhibitor , in patients with refractory metastatic soft-tissue sarcoma［J］.Clin Cancer Res, 2018, 24(21)：5233-5238.
[17] JUDSON I, VERWEIJ J, GELDERBLOM H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial［J］. Lancet Oncol , 2014, 15(4)：4115-423.
[18] FREZZA A M , STACCHIOT TI S , GRONCHI A .Systemic treatment in advanced soft tissue sarcoma: what is standard , what is new ［J］ .BMC Med , 2017, 15(1)：109-120.
[19] VO K T, M AT T HAY K K, DUBOIS S G. Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma ［J. Clin Sarcoma Res, 2016, 6: 9-19.
[20] VERSCHRAEGEN C F, ARIAS-PULIDO H, LEE S J, et al. Phase Ⅰ B study of the combination of docetaxel, gemcitabine , and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Ax tell regimen ［J］. Ann Oncol , 2012, 23(3)：785-790.
[21] GARCÍA DEL M URO X , M AUREL J , et al .Phase Ⅱ trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas （GEIS） study ［J］.Invest New Drugs , 2018, 36(3)：468-475.